Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TH-302 + Doxorubicin in Soft Tissue Sarcoma
NCT01440088Phase 3Completed
- Sponsor
- Threshold Pharmaceuticals
- Start
- Sep 2011
- Primary completion
- Dec 2015
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of evofosfamide in soft tissue sarcoma (STS) (2 arms), sponsored by Threshold Pharmaceuticals. Primary endpoint: Overall Survival at 2 years. Started Sep 2011; status: completed.
02
Drugs
evofosfamide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT01440088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01440088.